The clinical stage biopharmaceutical company presented the safety and efficacy results from Part I of the Matins trial in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting.
During the ASCO poster presentation, Faron Pharmaceuticals said the ongoing phase I/II Matins clinical trial is investigating the tolerability, safety and efficacy of Clevegen (FP-1305), its wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.
According to Faron, data were presented on all 30 patients in Part I of the trial, who had advanced solid tumours and had exhausted all standard therapeutic options. The poster included previously announced data, reporting that Clevegen was well tolerated without dose-limiting toxicities; Clever-1 inhibition led to immune cell activation and downregulation of several checkpoint molecules; and Interferon gamma and chemokine CXCL10 responses were associated with clinical responses observed in target or non-target lesions.
Separately, Faron has also announced an update on Part II of the Matins trial study, which has begun, and that patient recruitment continues to be strong, despite the Covid-19 pandemic. The company said that Part II now contains cohorts of nine different cancers at 1.0 mg/kg dosing and three colorectal cancer (CRC) cohorts at 0.3, 1.0 and 3.0 mg/kg. Of these, the 0.3 mg/kg cohort has already recruited, with the additional two CRC cohorts expected to be recruited by mid-summer. Faron said it intends to present data from these test cohorts (ten patients at each dosing levels) to the FDA at the end-of-phase II meeting to obtain advice ahead of expansion into the pivotal Part III stage of the trial.
